S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:XNCR

Xencor - XNCR Price Target & Analyst Ratings

$34.20
+1.28 (+3.89%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$32.49
$34.49
50-Day Range
$24.79
$34.20
52-Week Range
$19.35
$35.92
Volume
497,968 shs
Average Volume
371,007 shs
Market Capitalization
$2.05 billion
P/E Ratio
71.25
Dividend Yield
N/A
Price Target
$47.50

Xencor Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 11 Analyst Ratings

Consensus Analyst Price Target

$46.89
37.10% Upside
High Prediction$58.00
Average Prediction$46.89
Low Prediction$36.00
TypeCurrent
2/2/22 to 2/2/23
1 Month Ago
1/3/22 to 1/3/23
3 Months Ago
11/4/21 to 11/4/22
1 Year Ago
2/2/21 to 2/2/22
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
9 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$46.89$48.89$50.86$54.78
Predicted Upside37.10% Upside66.16% Upside70.83% Upside37.25% Upside
Get Xencor Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.


XNCR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

XNCR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Xencor Stock vs. The Competition

TypeXencorMedical CompaniesS&P 500
Consensus Rating Score
3.09
2.65
2.46
Consensus RatingBuyBuyHold
Predicted Upside37.10% Upside1,302.23% Upside8.16% Upside
News Sentiment RatingPositive News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/30/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$42.00+30.64%
12/6/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
11/9/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$50.00 ➝ $48.00+62.88%
11/8/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$40.00 ➝ $36.00+33.53%
10/13/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeOutperform ➝ Strong-Buy$58.00+118.70%
9/21/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$37.00+34.01%
5/23/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$66.00 ➝ $42.00+78.34%
4/1/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Stavropoulos
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
2/24/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy$61.00 ➝ $55.00+74.71%
2/11/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$54.00+59.01%
1/21/2022Sumitomo Mitsui Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$60.00+72.27%
11/9/2021BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
9/28/2021Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$57.00 ➝ $50.00+47.36%
8/5/2021SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Chang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform$57.00 ➝ $53.00+70.64%
5/6/2021Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$52.00 ➝ $47.00+17.56%
2/24/2021Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderweight$31.00 ➝ $34.00-29.68%
8/5/2020Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mara Goldstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
5/10/2020Nomura
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSell$21.00-36.77%
(Data available from 2/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












XNCR Price Target - Frequently Asked Questions

What is Xencor's consensus rating and price target?

According to the issued ratings of 11 analysts in the last year, the consensus rating for Xencor stock is Buy based on the current 10 buy ratings and 1 strong buy rating for XNCR. The average twelve-month price prediction for Xencor is $46.89 with a high price target of $58.00 and a low price target of $36.00. Learn more on XNCR's analyst rating history.

Do Wall Street analysts like Xencor more than its competitors?

Analysts like Xencor more than other Medical companies. The consensus rating score for Xencor is 3.09 while the average consensus rating score for medical companies is 2.65. Learn more on how XNCR compares to other companies.

Does Xencor's stock price have much upside?

According to analysts, Xencor's stock has a predicted upside of 61.09% based on their 12-month price targets.

What analysts cover Xencor?

Xencor has been rated by Canaccord Genuity Group, Cowen, Cowen, EF Hutton Acquisition Co. I, and Royal Bank of Canada in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:XNCR) was last updated on 2/2/2023 by MarketBeat.com Staff